4D Molecular Therapeutics is a clinical-stage genetic medicine company reporting 56,379,402 shares of common stock outstanding as of November 9, 2026. The company continues to incur significant net losses and requires substantial additional capital to fund the development of its lead AAV product candidates, including 4D-150 and 4D-175.
4D Molecular Therapeutics reported Q3 2026 financial results and provided updates on its 4D-150 clinical programs, including the completion of randomization for the 4FRONT-2 Phase 3 trial in wet AMD. The company ended the quarter with $375 million in cash, which is expected to fund operations into the second half of 2028.
“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD.”
David Kirn, MD, Co-founder, President and Chief Executive Officer
4D Molecular Therapeutics CLO Scott Bizily Sells $21K of Stock
Scott Bizily, CLO, sold 1,635 shares of 4D Molecular Therapeutics, Inc. at $12.84 a share, worth $21K in total on Oct 16, 2026. Shares held after the trade: 8,617 (-15.9%).
4D Molecular Therapeutics Insider David Kirn Sells $750K of Stock
David Kirn sold 58,061 shares of 4D Molecular Therapeutics, Inc. at $12.92 a share, worth $750K in total on Oct 5, 2026. Shares held after the trade: 709,425 (-7.6%).
4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.